What is Veradermics?
Veradermics is a specialized biopharmaceutical enterprise focused on the development of innovative, non-hormonal treatments for a variety of dermatologic and aesthetic conditions. The company distinguishes itself through a robust pipeline that prioritizes oral therapies, aiming to address significant unmet medical needs in hair regrowth and skin health. By leveraging advanced molecular science, Veradermics seeks to disrupt traditional treatment paradigms, offering patients safer and more effective alternatives to existing hormonal interventions. Its market position is bolstered by a strategic focus on high-growth aesthetic segments, supported by a sophisticated network of institutional backers and life sciences investors.
How much funding has Veradermics raised?
Veradermics has raised a total of $616.3M across 4 funding rounds:
Series B
$75M
Series C
$150M
Private Equity
$135M
IPO
$256.3M
Series B (2024): $75M with participation from PhiFund Ventures, J.W. Childs Associates, Suvretta Capital Management, Longitude Capital, Osage University Partners, Connecticut Innovations, and Surveyor Capital
Series C (2025): $150M led by Marshall Wace, SR One, Columbia Threadneedle Investments US, Suvretta Capital Management, Infinitium, LifeSci Venture Partners, Longitude Capital, Viking Global Investors, and Invus
Private Equity (2025): $135M, investors not publicly disclosed
IPO (2026): $256.3M featuring Wellington Management and Lilly
Key Investors in Veradermics
Longitude Capital
Longitude Capital is a healthcare-focused venture capital firm that invests in biotechnology, medical technology, and health solutions companies, pairing sector expertise, flexible capital, and active partnership to help innovators scale and improve patient care.
Suvretta Capital Management
Suvretta Capital Management, LLC operates as an investment management company providing capital management, financial planning, and advisory services to clients in the State of New York.
SR One
SR One is a transatlantic biotechnology venture capital firm that invests in early and growth-stage life sciences companies developing novel therapeutics, providing hands-on strategic and operational support.
What's next for Veradermics?
Looking ahead, the recent capital injection will be instrumental in scaling Veradermics' clinical operations and expanding its research infrastructure. The company is expected to prioritize the advancement of its lead programs, focusing on rigorous clinical trial execution and regulatory engagement. As the firm matures, the strategic deployment of these funds will likely center on optimizing manufacturing processes and preparing for potential commercialization pathways. With a strong foundation of institutional support, Veradermics is poised to solidify its footprint in the global dermatology market, potentially exploring further indications for its proprietary therapeutic platform to drive long-term shareholder value.
See full Veradermics company page
